DUBLIN, July 12, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Post Menopausal Vaginal Atrophy Drugs Market 2016-2020" report to their offering.
The report forecasts the global PVA drugs market to grow at a CAGR of 7.13% during the period 2016-2020.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Non-estrogenic therapies in PVA treatment are a paradigm shift from systemic estrogen therapies such as creams, patches, and gels. In addition, the launch of late-stage pipeline products is expected to shift the attention from vaginal creams and OTC classes toward vaginal tablets and oral therapies.
According to the report, the Affordable Care Act has increased the number of insured women and has been a driving factor in the treatment-seeking behavior of people with this condition. The law puts in place comprehensive health insurance reforms that will roll out over four years and beyond. This provides Americans with better health security by putting in place comprehensive health insurance reforms that lower healthcare costs and expand the coverage.
Further, the report states that the market is currently served by generic products due to the patent expiries of branded products such as Premarin, which lost its patent in 2012.
- Pfizer Inc.
- Allergan Inc.
- Shionogi & Co. Ltd.
- Novo Nordisk A/S
- Teva Pharmaceutical Industries Ltd.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Overview: Vaginal atrophy
PART 06: Branded drug profiles
PART 07: Market landscape
PART 08: Market segmentation by drug class
PART 09: Geographical segmentation
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
PART 16: Appendix
For more information visit http://www.researchandmarkets.com/research/dvwrdn/global_post
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-post-menopausal-vaginal-atrophy-drugs-market-2016-2020---driven-by-favorable-healthcare-reforms-in-the-us---research-and-markets-300297186.html
SOURCE Research and Markets